Baldamus C A, Knobloch M, Koch K M
Int J Artif Organs. 1980 Jul;3(4):211-4.
In 14 stable ESRD patients an ABA cross-over study comparing conventional hemodialysis with post-dilution hemofiltration was performed in order to test the validity of clinical benefits reported for hemofiltration. No effect on blood-pressure could be observed in hypertensive hemofiltration patients when body weight was kept constant. The claimed positive effect of hemofiltration on hyperphosphatemia in dialysis patients could not be confirmed. A treatment with 3x81 I infusate per week seems to be insufficient treatment in regard to small molecule removal especially in heavy patients without any residual renal function. The decrease in urea nitrogen generation rate during the hemofiltration period might be the result of the lower small molecule removal in hemofiltration when compared to hemodialysis. The main clinical benefit of hemofiltration results from improved tolerance to volume removal due to improved hemodynamic stability during treatment.
在14例稳定的终末期肾病患者中进行了一项ABA交叉研究，比较了传统血液透析与后置稀释血液滤过，以检验有关血液滤过临床益处报道的有效性。当体重保持恒定时，高血压血液滤过患者的血压未观察到变化。血液滤过对透析患者高磷血症所宣称的积极作用未能得到证实。每周使用3次81I输注液进行治疗，对于小分子清除而言似乎是不足的治疗，尤其是对于没有任何残余肾功能的重症患者。与血液透析相比，血液滤过期间尿素氮生成率的降低可能是血液滤过中小分子清除较低的结果。血液滤过的主要临床益处源于治疗期间血流动力学稳定性改善，从而提高了对容量清除的耐受性。
